Introduction: Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative. Currently, there are no evidence-based guidelines for the treatment of postoperative macular edema. Intravitreal dexamethasone (DEX) could be effective by its anti-inflammatory effect. We examined the functional and morphological results of treatment with 0.7 mg intravitreal DEX implant (Ozurdex®). Methods: In an observational study, we analyzed visual acuity (logMAR), intraocular pressure (IOP), clinical findings, and the central macular thickness (CMT, optical coherence tomography [OCT] Spectralis®, Heidelberg Engineering, 30° macular scan, 19 scans) of 12 eyes before and 1 month after the last DEX implantation (off-label use, Ozurdex®, Allergan, Inc., Irvine, CA, USA) for macular edema after cataract surgery or vitrectomy. Re-implantation was performed when OCT showed new intraretinal fluid along with a decrease in the patient's visual acuity. The mean follow-up was 14.4 ± 10.6 months. Results: Twelve eyes of 12 patients (4 female, 8 male) with a mean age of 62.6 ± 11.9 years were treated with a mean of 2.5 ± 1.6 intravitreal DEX implant injections. Prior to injection, the visual acuity was 0.74 ± 0.34 logMAR and the CMT was 608 ± 129 µm. One month after the last injection (after a mean of 437 ± 322 days), the CMT normalized (300 ± 90 µm, p < 0.01) in all cases with a visual acuity of 0.49 ± 0.43 logMAR (p < 0.01). After 8.1 ± 5.3 months, recurring macular edema could be completely reduced by re-injection in 66% (8 patients). Four patients had no recurrence. Postinjection, the mean IOP was 17.4 ± 6.8 mm Hg. Postinjection, 7 patients required topical antiglaucomatous therapy. Conclusions: Treatment with an intravitreal DEX implant is an effective therapy for postoperative macular edema. Each injection leads to a complete resorption of the edema with a significant increase in visual acuity.

Keywords:
Postoperative macular edema, Irvine-Gass syndrome, intravitreal injection, Dexamethasone implant
1.
Mohammadpour M, Jafarinasab MR, Javadi MA: Outcomes of acute postoperative inflammation after cataract surgery. Eur J Ophthalmol 2007;17:20-28.
2.
Jampol LM, Sanders DR, Kraff MC: Prophylaxis and therapy of aphakic cystoid macular edema. Surv Ophthalmol 1984;28(suppl): 535-539.
3.
Stark WJ Jr, Maumenee AE, Fagadau W, Datiles M, Baker CC, Worthen D, Klein P, Auer C: Cystoid macular edema in pseudophakia. Surv Ophthalmol 1984;28(suppl):442-451.
4.
Miyake K, Ibaraki N: Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47(suppl 1):S203-S218.
5.
Xu H, Chen M, Forrester JV, Lois N: Cataract surgery induces retinal pro-inflammatory gene expression and protein secretion. Invest Ophthalmol Vis Sci 2011;52:249-255.
6.
Nelson ML, Martidis A: Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 2003;14:39-43.
7.
Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE: Macular edema. Surv Ophthalmol 2004;49:470-490.
8.
Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, Wu L; Pan-American Collaborative Retina Study Group: Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 2009;116:1481-1487, 1487.e1.
9.
Ghasemi Falavarjani K, Parvaresh MM, Modarres M, Hashemi M, Samiy N: Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review. J Ophthalmic Vis Res 2012;7:235-239.
10.
Zarranz-Ventura J, Carreno E, Johnston RL, Mohammed Q, Ross AH, Barker C, Fonollosa A, Artaraz J, Pelegrin L, Adan A, Lee RW, Dick AD, Sallam A: Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection Frequency. Am J Ophthalmol 2014;158:1136-1145.e5.
11.
Hunter RS, Lobo AM: Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol 2011;5:1613-1621.
12.
Myung JS, Aaker GD, Kiss S: Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol 2010;4:1423-1426.
13.
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM, Ozurdex HSG: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-553.
14.
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MSG: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-1914.
15.
Parravano M, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M: Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Ophthalmic Res 2014;51:153-160.
16.
Irvine SR: A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol 1953;36:599-619.
17.
Gass JD, Norton EW: Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol 1966;76:646-661.
18.
Benitah NR, Arroyo JG: Pseudophakic cystoid macular edema. Int Ophthalmol Clin 2010;50:139-153.
19.
Catier A, Tadayoni R, Massin P, Gaudric A: Advantages of acetazolamide associated with anti-inflammatory medications in postoperative treatment of macular edema (in French). J Fr Ophtalmol 2005;28:1027-1031.
20.
Cox SN, Hay E, Bird AC: Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988;106:1190-1195.
21.
Schmitz K, Maier M, Clemens CR, Hohn F, Wachtlin J, Lehmann F, Bertelmann T, Rudiger K, Horn M, Bezatis A, Spital G, Meyer CH; German Retinal Vein Occlusion Group: Reliability and safety of intravitreal Ozurdex injections. The ZERO study (in German). Ophthalmologe 2014;111:44-52.
22.
Koutsandrea C, Moschos MM, Brouzas D, Loukianou E, Apostolopoulos M, Moschos M: Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: optical coherence tomography and multifocal electroretinography study. Retina 2007;27:159-164.
23.
Dutra Medeiros M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B: Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. Invest Ophthalmol Vis Sci 2013;54:3320-3324.
24.
Bellocq D, Korobelnik JF, Burillon C, Voirin N, Dot C, Souied E, Conrath J, Milazzo S, Massin P, Baillif S, Kodjikian L: Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol 2015;99:979-983.
25.
London NJ, Chiang A, Haller JA: The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011;28:351-366.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.